PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 34775781-12 2022 These data support combined SGLT2 inhibitor and GLP-1 RA therapy in type 2 diabetes. Radium 54-56 glucagon like peptide 1 receptor Homo sapiens 48-53 27459537-5 2016 PATIENT AND METHODS: We treated an insulin-dependent T2-WFS patient with the GLP-1-RA exenatide for 9 weeks. Radium 83-85 glucagon like peptide 1 receptor Homo sapiens 77-82 25382096-12 2014 Due to the differences in pharmacokinetics, efficacy, rates of adverse effects, and administration requirements within the GLP-1 RA class, each agent should be evaluated independently. Radium 129-131 glucagon like peptide 1 receptor Homo sapiens 123-128 33818009-5 2021 There was a significant difference in the percentage of individuals achieving >=5% weight loss after 3, 6, and 9 months, with most occurring in the GLP-1-RA-based WLP group. Radium 154-156 glucagon like peptide 1 receptor Homo sapiens 148-153 33818009-7 2021 CONCLUSIONS: GLP-1-RA-based WLP therapies were found to be more effective for treating post-bariatric weight regain than non-GLP-1-RA-based WLP or ILM, regardless of surgery type. Radium 19-21 glucagon like peptide 1 receptor Homo sapiens 13-18 34448208-6 2022 RESULTS: Ten studies included, summarizing GLP1-RA use in 23 PWS patients (age, 13-37 years), who had used either exenatide (n = 14) or liraglutide (n = 9) over a duration of 14 weeks to 4 years. Radium 48-50 glucagon like peptide 1 receptor Homo sapiens 43-47 34668637-9 2022 Study findings remained consistent when restricted to GLP-1 RA users. Radium 60-62 glucagon like peptide 1 receptor Homo sapiens 54-59 34866306-12 2022 At week 52, HbA1c decreased by 0.46% with imeglimin monotherapy, by 0.56% - 0.92% with imeglimin as oral combination therapy, and by 0.12% with injectable GLP1-RA combination therapy. Radium 160-162 glucagon like peptide 1 receptor Homo sapiens 155-159 34745006-8 2021 The cardio- and reno-protective effects of GLP-1-RA are at least in part related to the interaction with RAAS. Radium 49-51 glucagon like peptide 1 receptor Homo sapiens 43-48 34217774-1 2021 AIM: We evaluated the effect of the latest GLP-1 RA semaglutide on tongue fat storage in obese women. Radium 49-51 glucagon like peptide 1 receptor Homo sapiens 43-48 34997102-9 2022 High baseline HbA1c, the addition of GLP-1 RA treatment modality, and in-hospital initiation of GLP-1 RA treatment were identified as significant contributing factors to HbA1c reduction. Radium 102-104 glucagon like peptide 1 receptor Homo sapiens 96-101 34098057-1 2021 AIM: Previous studies have found reduced concentrations of both leptin and resistin after glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment; however, the evidence in this field is inconclusive. Radium 138-140 glucagon like peptide 1 receptor Homo sapiens 90-122 34098057-1 2021 AIM: Previous studies have found reduced concentrations of both leptin and resistin after glucagon-like peptide-1 receptor agonist (GLP-1 RA) treatment; however, the evidence in this field is inconclusive. Radium 138-140 glucagon like peptide 1 receptor Homo sapiens 132-137 34098057-8 2021 CONCLUSION: The results of this meta-analysis of randomized controlled trials suggest that GLP-1 RA therapy reduces both leptin and resistin levels. Radium 97-99 glucagon like peptide 1 receptor Homo sapiens 91-96 34135013-7 2021 The 60-day mortality was 3.11% (387 of 12,446), with 2.06% (138 of 6,692) for GLP1-RA use, 2.32% (85 of 3,665) for SGLT2i use, and 5.67% (199 of 3,511) for DPP4i use. Radium 83-85 glucagon like peptide 1 receptor Homo sapiens 78-82 35194917-6 2022 The overall analysis results showed that GLP-1 RA improved glycemic control without increasing the risk of hypoglycemic events. Radium 47-49 glucagon like peptide 1 receptor Homo sapiens 41-46 35134170-3 2022 However, the role of angiotensin II and other vasoactive hormones on GLP-1 RA treatment has not been clearly defined. Radium 75-77 glucagon like peptide 1 receptor Homo sapiens 69-74 35491520-9 2022 Further research into the effect of adding Gla-300 to GLP-1 RA therapy is warranted. Radium 60-62 glucagon like peptide 1 receptor Homo sapiens 54-59 35373878-4 2022 During follow-up, 673 participants receiving GLP-1 RA treatment (8.7%) and 416 participants receiving placebo (11.2%) had a cardiovascular event. Radium 51-53 glucagon like peptide 1 receptor Homo sapiens 45-50 35175551-7 2022 Here, we review evidence on GLP-1 RA use in people living with T2DM and CKD and summarize renal outcomes from clinical studies. Radium 34-36 glucagon like peptide 1 receptor Homo sapiens 28-33 35059245-6 2022 Forty-six percent of the subjects in the daily GLP-1 RAs group reported that the incidence of forgetting injections of GLP-1 RA was decreased. Radium 125-127 glucagon like peptide 1 receptor Homo sapiens 47-52 35101924-4 2022 RESEARCH DESIGN AND METHODS: A retrospective cohort study among patients with T2DM initiating injectable GLP-1 RA therapy was conducted using the Clinical Practice Research Datalink that includes primary care medical records for 13 million patients in the UK. Radium 111-113 glucagon like peptide 1 receptor Homo sapiens 105-110 35059245-6 2022 Forty-six percent of the subjects in the daily GLP-1 RAs group reported that the incidence of forgetting injections of GLP-1 RA was decreased. Radium 125-127 glucagon like peptide 1 receptor Homo sapiens 119-124 33400403-4 2021 MATERIALS AND METHODS: Prospective cohort study of men starting GLP-1 RA therapy for type 2 diabetes mellitus. Radium 70-72 glucagon like peptide 1 receptor Homo sapiens 64-69 33565209-0 2021 Switching to iGlarLixi vs Continuation of Daily or Weekly GLP-1 RA in Insufficiently Controlled Type 2 Diabetes: A LixiLan-G Trial Subgroup Analysis by HbA1c and GLP-1 RA Use at Screening. Radium 64-66 glucagon like peptide 1 receptor Homo sapiens 58-63 33400403-9 2021 CONCLUSION: GLP-1 RA therapy improves weight and HbA1c without adverse effects on testosterone. Radium 18-20 glucagon like peptide 1 receptor Homo sapiens 12-17 33835520-1 2021 AIM: Previous studies have reported an elevation in adiponectin concentrations using glucagon-like peptide-1 receptor agonists (GLP-1 RA) therapy; however, this possible pleiotropic effect is still uncertain. Radium 134-136 glucagon like peptide 1 receptor Homo sapiens 85-117 33864629-0 2021 Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis. Radium 46-48 glucagon like peptide 1 receptor Homo sapiens 40-45 33864629-3 2021 METHODS: This retrospective cohort analysis presents longitudinal data from approximately 7500 French retail pharmacies that filled GLP-1-RA prescriptions for GLP-1 RA-naive patients with T2D ("index therapy": dulaglutide; once-weekly exenatide [exenatide QW]; twice-daily exenatide [exenatide BID]; liraglutide) between January 2015 and December 2016 (follow-up >= 12 months). Radium 138-140 glucagon like peptide 1 receptor Homo sapiens 132-137 33864629-3 2021 METHODS: This retrospective cohort analysis presents longitudinal data from approximately 7500 French retail pharmacies that filled GLP-1-RA prescriptions for GLP-1 RA-naive patients with T2D ("index therapy": dulaglutide; once-weekly exenatide [exenatide QW]; twice-daily exenatide [exenatide BID]; liraglutide) between January 2015 and December 2016 (follow-up >= 12 months). Radium 165-167 glucagon like peptide 1 receptor Homo sapiens 159-164 33835520-6 2021 RESULTS: A meta-analysis of 20 randomized controlled trials involving 1,497 individuals demonstrated a significant increase in adiponectin levels after GLP-1 RA administration (WMD: 0.59 mug/mL, 95% CI: 0.10, 1.08, p = 0.02). Radium 158-160 glucagon like peptide 1 receptor Homo sapiens 152-157 33854754-5 2021 We compared the incidence of inpatient, emergency room, or outpatient diagnosis of GUI (bacterial and mycotic) within 6 months of SGLT2i or GLP1-RA initiation. Radium 145-147 glucagon like peptide 1 receptor Homo sapiens 140-144 33854754-8 2021 Results: One hundred and thirty-three patients were initiated on SGLT2i therapy and 341 patients newly initiated on GLP1-RA therapy. Radium 121-123 glucagon like peptide 1 receptor Homo sapiens 116-120 33581878-13 2021 GLP1-RA use also increased, but observed usage remained lower than SGLT2 inhibitors. Radium 5-7 glucagon like peptide 1 receptor Homo sapiens 0-4 33292155-7 2021 LEADER, REWIND and SUSTAIN-6 trials have demonstrated reduction in rates of major adverse cardiovascular events with active GLP-1 RA treatment but ELIXA, PIONEER 6 and EXSCEL have been neutral. Radium 130-132 glucagon like peptide 1 receptor Homo sapiens 124-129 32910778-6 2020 LIMITATIONS: There were relatively small numbers of available publications, some heterogeneity regarding protocols, and differences in the GLP-1 RA compound used. Radium 145-147 glucagon like peptide 1 receptor Homo sapiens 139-144 30786725-5 2019 RESULTS: In total, data from 8 trials and 77 242 patients, 42 920 (55.6%) in GLP1-RA trials, and 34 322 (44.4%) in SGLT2i trials, were included. Radium 82-84 glucagon like peptide 1 receptor Homo sapiens 77-81 33300091-4 2021 RESULTS: The analysis included 932 eligible patients with T2DM who had their first GLP-1 RA prescription (index date) between September 2016 and July 2018. Radium 89-91 glucagon like peptide 1 receptor Homo sapiens 83-88